203P - Molecular analysis of predictive biomarkers-KRAS, BRAF, NRAS and PIK3CA in colon cancer and correlation of clinico-pathological features with mutat...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Biomarkers
Colon and Rectal Cancer
Presenter Harshali Patil
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors H.A. Patil1, S. Gada Saxena1, C. Barrow2, R.K. Kanwar3, J.R. Kanwar3, A. Kapat1
  • 1Dhirubhai Ambani Life Sciences Centre, Reliance Life Sciences Pvt Ltd,, 400701 - Mumbai/IN
  • 2School Of Life And Environmental Sciences,centre For Chemistry And Biotechnology, Deakin University, 3220 - Melbourne/AU
  • 3School Of Medicine, Centre For Molecular And Medical Research, Faculty Of Health, Deakin University, 3216 - Melbourne/AU

Abstract

Background

Colorectal cancer (CRC) is one of the leading causes of cancer mortality worldwide. In this study, the prevalence of KRAS, BRAF, NRAS and PIK3CA mutations was examined in 203 CRC patients from India. The correlation with geographic distribution and clinico-pathological characteristics was studied. We also evaluated the correlation between clinicopathological features and the therapeutic response in 25 Indian CRC cases.

Methods

Mutations in KRAS (exon 2, exon 3), BRAF (exon 15), NRAS (exon 2, exon 3) and PIK3CA (exon 9, exon 20) genes were tested using Sanger Sequencing in 203 CRC patients from all over India during the period from January 2013 to July 2016.Treatment data was studied in 25 patients on the basis of different clinicopathological features. The overall survival was plotted using GraphPad Prism 7 software.

Results

The prevalence of KRAS, BRAF, NRAS and PIK3CA mutations was found to be 24%, 6%, 2% and 4% respectively. There was statistically significant association between KRAS mutations with age and tumor differentiation (p 

Conclusions

KRAS, BRAF, NRAS and PIK3CA mutations in Indian CRC patients occur at lower levels compared to that in the population of Western developed nations. However, life expectancy has not increased drastically in these years. This study supports the hypothesis that clinical and pathological characteristics are better determinants of prognosis in CRC patients.

Clinical trial indentification

Legal entity responsible for the study

Reliance Life Sciences

Funding

Reliance Life Sciences

Disclosure

All authors have declared no conflicts of interest.